ELAN
Elanco Animal Health Incorporated · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers):
holder breadth +6.2% ·
share flow -15.4% ·
net new positions +5.9%
· formula
Ownership fragmentation: more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 276.62K | $5.90M | n/a | n/a |
| Q2 2026 | 130 | +5 | 426.69M | $10.50B | +12 | −6 |
| Q1 2026 | 127 | -2 | 403.59M | $9.65B | +6 | −9 |
| Q4 2025 | 128 | +1 | 433.50M | $9.81B | +4 | −2 |
| Q3 2025 | 20 | -1 | 348.71M | $7.02B | n/a | −2 |
| Q2 2025 | 19 | +2 | 313.01M | $4.47B | +3 | −1 |
| Q1 2025 | 14 | -2 | 167.03M | $1.75B | +1 | −3 |
| Q4 2024 | 16 | -2 | 168.00M | $2.03B | n/a | −2 |
| Q3 2024 | 17 | +1 | 175.40M | $2.58B | +1 | n/a |
| Q2 2024 | 16 | n/a | 207.32M | $2.99B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Dodge & Cox ✦ | 83.32M | -0.3% | $1.22B | 0.7% | ▼ Trim | 2 | SEC ↗ |
| 2 | PRIMECAP Management ✦ | 52.58M | -0.4% | $772.33M | 0.6% | ▼ Trim | 2 | SEC ↗ |
| 3 | Millennium Management ✦ | 8.99M | -4.5% | $132.08M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 7.87M | +0.8% | $115.62M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 5 | Citadel Advisors ✦ | 7.49M | -41.4% | $110.09M | 0.1% | ▼ Trim | 2 | SEC ↗ ×2 |
| 6 | Wellington Management ✦ | 4.01M | +19.2% | $58.87M | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 7 | Norges Bank ✦ (passive) | 3.57M | -7.9% | $52.45M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 8 | T. Rowe Price ✦ | 3.04M | -89.2% | $44.59M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 9 | Point72 Asset Management ✦ | 1.34M | New | $19.71M | 0.1% | New | 1 | SEC ↗ |
| 10 | D. E. Shaw & Co. ✦ | 1.03M | -59.4% | $15.11M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 11 | Adage Capital Partners ✦ | 700.00K | -49.9% | $10.28M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 12 | Renaissance Technologies ✦ | 479.54K | +1853.8% | $7.04M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | Marshall Wace ✦ | 398.50K | -71.2% | $5.85M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 14 | Gotham Asset Management ✦ | 338.96K | +111.1% | $4.98M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 197.44K | +177.2% | $2.90M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 16 | Two Sigma Investments ✦ | 35.33K | -1.4% | $519,042 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 17 | Arrowstreet Capital ✦ | 25.68K | +11.1% | $377,195 | 0.0% | ▲ Add | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $19.71M | 0.1% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 512 holders, 543.55M shares, $11.98B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Director · 40.00K sh @ 23.40 · $935,920
Officer · GC AND CORP SEC · 4.00K sh @ 23.58 · $94,273
Director · 5.00K sh @ 21.82 · $109,100
Director · 10.00K sh @ 23.68 · $236,850
Officer · EVP and CFO · 4.20K sh @ 23.08 · $96,926
Open-market sales (S)
Officer · 4.35K sh · $100,050
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology